Alfred Slanetz

Company: Geneius Biotechnology, Inc.

Job title: President & Chief Executive Officer

Seminars:

Delving into the Tumour Microenvironment to Improve Understanding of the Immunosuppressive Environment to Increase Effectivity of Neoantigen Therapies 12:05 pm

Due to the great heterogeneity of tumours, they can evolve capabilities to allow them to escape and evade the immune system. Moreover, the tumour microenvironment may have compounds or signals which block interactions between therapies and the tumour. Therefore, in order to create the most effective and immunogenic therapies, these mechanisms need to be understood…Read more

day: Pre-Conference Day